Document is current
Any future updates will be listed below
-
Authors
Babazada, Hasan https://orcid.org/0000-0001-8705-2396
Martorano, Paul
Lee, Hsiaoju
Geng, Shuyao
Batra, Vandana
Maris, John M.
Pryma, Daniel A.
Gitto, Sarah B.
Farwell, Michael D.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA219006)
National Institutes of Health (R35CA220500)
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 9 May 2025
First Online: 1 June 2025
Declarations
:
: All animal experiments were performed in accordance with the Institutional Animal Care and Use Committee guidelines.
: Not applicable.
: Not applicable.
: Daniel A Pryma serves on the scientific advisory board for Molecular Targeting Technologies, Inc. and Trevarx, is a DSMB member for ITM, receives grant funding from Lantheus, Point Biopharma, Rayze Bio, and Fusion Pharmaceuticals, receives honoraria from Molecular Targeting Technologies, Inc., and holds IP for PTT, which is licensed to Trevarx. All other co-authors declared no Competing Interests.
